The emerging role of PARP inhibitors in prostate cancer.

Marco Stellato, Valentina Guadalupi, Pierangela Sepe, Alessia Mennitto, Mélanie Claps, Emma Zattarin, Elena Verzoni, Riccardo Valdagni, Filippo Gm De Braud, Daniele Santini, Giuseppe Tonini, Giuseppe Procopio

Research output: Contribution to journalArticlepeer-review


INTRODUCTION: In prostate cancer , there has recently been an emerging interest in mutations in genes belonging to the homologous recombination repair (HRR) pathway and in the inhibition of poly (ADP-ribose) polymerase (PARP) proteins. AREAS COVERED: Mutations in the HRR genes, including BRCA1, BRCA2, and Ataxia-Telangiesctasia mutated (ATM), have been reported in prostate cancer, with different incidence in the localized and advanced settings. The PARP enzyme complex is involved in repair of DNA damage and its inhibition causes the accumulation of DNA mutations in HRR deficient cells. Several PARP inhibitors (PARPi) are under development, such as olaparib, talazoparib, niraparib, rucaparib, and veliparib. In metastatic castration resistant prostate cancer (mCRPC), olaparib has been the most studied and its clinical efficacy has been validated in a phase III clinical trial. Rucaparib and niraparib have also shown promising results in the preliminary analyzes of two phase II trials, while talazoparib is currently under development. EXPERT OPINION: PARPi have become part of the treatment of mCRPC. Early results of combination therapy with PARPi and new hormonal therapy are promising and are supported by a strong biological rationale. Current results need to be validated in randomized phase III-controlled trials in order to translate the use of PARPi into real world practice.
Original languageEnglish
JournalExpert Review of Molecular Diagnostics
Issue number8
Publication statusPublished - Aug 1 2020


Dive into the research topics of 'The emerging role of PARP inhibitors in prostate cancer.'. Together they form a unique fingerprint.

Cite this